Unmet Needs in the Management of Atrial Fibrillation (AF)
LIVE UPDATE FROM AHA24: What do we know about antiplatelets added to anticoagulation in patients with AF?
Best Practices for Implementing Dual Endothelin Angiotensin Receptor Antagonist Therapeutics in Patients with IgAN
Update on Emerging Anticoagulants
Best Practices for Implementing Dual Endothelin Angiotensin Receptor Antagonist Therapeutics in Patients with IgAN
Update From ESC24: New Data on Non-Statin Lipid Lowering Therapies and Reduced CV Risk
MS MAILBAG: Experts address common questions from AcademicCME MedEd programs on Multiple Sclerosis
2a) Feel free to send more ❓❓ to @ms_cme by DM anytime! This CE/#CME accredited program was supported by independent educational grants from Bristol Myers Squibb; EMD Serono; Mylan Specialty L.P., a Viatris Company; Sandoz; Sanofi; and TG Therapeutics, Inc. — MultipleSclerosis_CME (@ms_cme) July 9, 2024 2c) (cont)Aaron Miller MD; Clyde Markowitz MD; Robert Naismith […]
Biosimilars in MS: Overview
2) This program, intended for an audience of #HCPs, is supported by an independent educational grant from Sandoz. Statement of accreditation & faculty disclosures at https://t.co/QO3HNwRSPJ. FOLLOW US & earn CE/#CME at https://t.co/F9LsuViSoe.#FOAMed #neurotwitter #MStwitter — MultipleSclerosis_CME (@ms_cme) June 25, 2024 4a) What is a #biosimilar drug in the context of #MS tx?A) A medication […]
Best Practices for Implementing Dual Endothelin Angiotensin Receptor Antagonist Therapeutics in Patients with IgAN
The Potential for BTK Inhibitors to Improve Outcomes in Patients with Multiple Sclerosis
2) This program is supported by an educational grant from Sanofi and is intended for an audience of #healthcare providers. Accreditation statement and author disclosures at https://t.co/QO3HNwRSPJ. FOLLOW US for expert-led education in #MS management! — MultipleSclerosis_CME (@ms_cme) January 3, 2023 4) In #MS, #BTKi may stop #B_cells from attacking #myelin. The idea of targeting […]